| Cat. No. | Product Name | Target | Signaling Pathways |
|---|---|---|---|
| T22609 | BMS-378806 | Others | Others |
| BMS-378806 is a novel attachment inhibitor of HIV (EC50: 2.68±1.64nM, 26.5±3.5nM, 2.94±2.01nM,15.5±6.8nM, 3.46±0.81nM, 1.47±0.63nM and 0.85±0.13nM for LAI(T), SF-2(T),NL4-3(T), Bal(M), SF-162(M), JRFL(M) and TLAV(dual), respectively). | |||
| T6418 |
BMS-378806
BMS378806,BMS-806,1-[(2R)-4-苯甲酰基-2-甲基-1-哌嗪基]-2-(4-甲氧基-1H-吡咯并[2,3-B]吡啶-3-基)-1,2-乙二酮 |
gp120/CD4; HIV Protease | Immunology/Inflammation; Microbiology/Virology; Proteases/Proteasome |
| BMS378806 是一种 HIV-1 抑制剂，可选择性抑制 HIV-1 gp120 结合到 CD4 受体，EC50为 0.85-26.5 nM。 | |||
| T69371 | BMS 378806 | ||
| BMS-378806 is an orally bioavailable HIV-1 inhibitor that interferes with gp120-CD4 interaction. | |||
沪公网安备 31010602006700号
